Therefore, our findings demonstrating therapeutic benefit of Tubastatin A in PAH models combined to the fact that HDAC6 has limited and nonlethal implication in physiological processes41 and is minimally expressed in lung control cells make it a promising candidate towards therapeutic implementation in human PAH. Here, HDAC6 is linked to pulmonary arterial hypertension.